These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 30089401)

  • 1. Possible Causes of Failing to Meet Primary Endpoints: A Systematic Review of Randomized Controlled Phase 3 Clinical Trials in Patients With Non-Small Cell Lung Cancer.
    Ikeda M; Ochibe T; Tohkin M
    Ther Innov Regul Sci; 2019 May; 53(3):324-331. PubMed ID: 30089401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surrogate endpoints for overall survival in lung cancer trials: a review.
    Fiteni F; Westeel V; Bonnetain F
    Expert Rev Anticancer Ther; 2017 May; 17(5):447-454. PubMed ID: 28399678
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in endpoint selection and result interpretation in advanced non-small cell lung cancer clinical trials published between 2000 and 2012: A retrospective cohort study.
    Fernández-López C; Calleja-Hernández MÁ; Balbino JE; Cabeza-Barrera J; Expósito-Hernández J
    Thorac Cancer; 2019 Apr; 10(4):904-908. PubMed ID: 30868737
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression-free survival and one-year milestone survival as surrogates for overall survival in previously treated advanced non-small cell lung cancer.
    Zhao S; Zhang Z; Zhang Y; Hong S; Zhou T; Yang Y; Fang W; Zhao H; Zhang L
    Int J Cancer; 2019 Jun; 144(11):2854-2866. PubMed ID: 30430561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
    Hua T; Gao Y; Zhang R; Wei Y; Chen F
    BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of combined therapy inhibiting EGFR and VEGF pathways in patients with advanced non-small-cell lung cancer: a meta-analysis of 16 phase II/III randomized trials.
    Zhao Y; Wang H; Shi Y; Cai S; Wu T; Yan G; Cheng S; Cui K; Xi Y; Qi X; Zhang J; Ma W
    Oncotarget; 2017 Jan; 8(4):7014-7024. PubMed ID: 27690345
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reporting trends of outcome measures in phase II and phase III trials conducted in advanced-stage non-small-cell lung cancer.
    Ghimire S; Kyung E; Kim E
    Lung; 2013 Aug; 191(4):313-9. PubMed ID: 23715997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endpoints in phase II trials for advanced non-small cell lung cancer.
    Mandrekar SJ; Qi Y; Hillman SL; Allen Ziegler KL; Reuter NF; Rowland KM; Kuross SA; Marks RS; Schild SE; Adjei AA
    J Thorac Oncol; 2010 Jan; 5(1):3-9. PubMed ID: 19884856
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
    Pilz LR; Manegold C; Schmid-Bindert G
    Transl Lung Cancer Res; 2012 Mar; 1(1):26-35. PubMed ID: 25806152
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non-Small Cell Lung Cancer.
    Hashim M; Pfeiffer BM; Bartsch R; Postma M; Heeg B
    Value Health; 2018 Jan; 21(1):9-17. PubMed ID: 29304946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adoption of multiple primary endpoints in phase III trials of systemic treatments in patients with advanced solid tumours. A systematic review.
    Zichi C; Paratore C; Gargiulo P; Mariniello A; Reale ML; Audisio M; Bungaro M; Caglio A; Gamba T; Perrone F; Di Maio M
    Eur J Cancer; 2021 May; 149():49-60. PubMed ID: 33823362
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Postprogression survival in patients with advanced non-small-cell lung cancer who receive second-line or third-line chemotherapy.
    Hayashi H; Okamoto I; Taguri M; Morita S; Nakagawa K
    Clin Lung Cancer; 2013 May; 14(3):261-6. PubMed ID: 23107465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution.
    Nickolich M; Babakoohi S; Fu P; Dowlati A
    Clin Lung Cancer; 2014 May; 15(3):207-12. PubMed ID: 24485231
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of clinical characteristics on outcomes from maintenance therapy in non-small cell lung cancer: A systematic review with meta-analysis.
    Zhou F; Jiang T; Ma W; Gao G; Chen X; Zhou C
    Lung Cancer; 2015 Aug; 89(2):203-11. PubMed ID: 26115839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Locally advanced non-small cell lung cancer: do we know the questions? A survey of randomized trials from 1966-1993.
    Brundage MD; Mackillop WJ
    J Clin Epidemiol; 1996 Feb; 49(2):183-92. PubMed ID: 8606319
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of quality of life in advanced non-small-cell lung cancer: an overview of recent randomized trials.
    Saad ED; Adamowicz K; Katz A; Jassem J
    Cancer Treat Rev; 2012 Oct; 38(6):807-14. PubMed ID: 22445316
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Progression-free and overall survival in patients with relapsed/refractory germ cell tumors treated with single-agent chemotherapy: endpoints for clinical trial design.
    Feldman DR; Patil S; Trinos MJ; Carousso M; Ginsberg MS; Sheinfeld J; Bajorin DF; Bosl GJ; Motzer RJ
    Cancer; 2012 Feb; 118(4):981-6. PubMed ID: 21792865
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An overview of randomized clinical trials in metastatic breast cancer: variables affecting regulatory drug approval.
    Conde-Estévez D; Tusquets I; Servitja S; Martínez-García M; Salas E; Albanell J
    Anticancer Drugs; 2014 Oct; 25(9):992-7. PubMed ID: 24892723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The changing landscape of phase II/III metastatic NSCLC clinical trials and the importance of biomarker selection criteria.
    Gentzler RD; Yentz SE; Johnson ML; Rademaker AW; Patel JD
    Cancer; 2014 Dec; 120(24):3853-8. PubMed ID: 25155290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
    Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.